کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
5891302 1568162 2012 4 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Changes in vitamin D metabolites during teriparatide treatment
موضوعات مرتبط
علوم زیستی و بیوفناوری بیوشیمی، ژنتیک و زیست شناسی مولکولی زیست شناسی تکاملی
پیش نمایش صفحه اول مقاله
Changes in vitamin D metabolites during teriparatide treatment
چکیده انگلیسی

Parathyroid hormone (PTH) increases the conversion of 25-hydroxyvitamin D [25(OH)D] to 1,25 dihydroxyvitamin D [1,25(OH)2D]. The purpose of this study was to assess the changes in serum concentration of vitamin D metabolites 1,25 dihydroxyvitamin D [1,25(OH)2D] and 25-hydroxyvitamin D [25(OH)D] during teriparatide 20 μg/day (teriparatide) therapy in the double-blind Fracture Prevention Trial of postmenopausal women with osteoporosis and in the male study of men with osteoporosis. Patients were randomized to teriparatide or placebo and received daily supplements of calcium 1000 mg and vitamin D 400-1200 IU. Serum concentrations of 1,25(OH)2D and 25(OH)D were measured. In women (N = 336), median 1,25(OH)2D concentrations at 1 month increased from baseline by 27% (P < 0.0001) in the teriparatide group versus − 3% (P = 0.87) in the placebo group (between group P < 0.0001). At 12 months, the increase was 19% (P < 0.0001) in the teriparatide group versus − 2% (P = 0.23) in the placebo group (P < 0.0001). Median 25(OH)D concentrations at 12 months decreased by 19% (P < 0.0001) in the teriparatide group versus 0% (P = 0.13) in the placebo group (P < 0.0001). In men (N = 287), median 1,25(OH)2D concentrations at 1 month increased by 22% (P < 0.0001) in the teriparatide group versus 0% (P = 0.99) in the placebo group (P < 0.0001). At 12 months, the increase was 14% (P < 0.0001) in the teriparatide group versus 5% (P = 0.004) in the placebo group (P = 0.17). Median 25(OH)D concentrations at 12 months decreased by 11% (P = 0.001) in the teriparatide group versus an increase of 1% (P = 0.20) in the placebo group (P = 0.003). Therefore, treatment with teriparatide increases 1,25(OH)2D concentrations and decreases 25(OH)D concentrations.

► Twelve months of teriparatide treatment (20 μg/day) in men and postmenopausal women, significantly increased 1,25(OH)2D and significantly decreased 25(OH)D. ► 1,25(OH)2D levels peaked at 1 month of treatment and persisted over 1 year. ► Results suggest a conversion of 25(OH)D to biologically active 1,25(OH)2D. ► Increase of 1,25(OH)2D may contribute to the biological effect of teriparatide treatment.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Bone - Volume 50, Issue 6, June 2012, Pages 1368-1371
نویسندگان
, , , ,